Dr. Paulo A. Garcia co-invented the Flowfect® technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.

Cullen R. Buie, Ph.D. is a Tenured Professor of Mechanical Engineering at MIT and co-inventor of the high-throughput genetic modification technology. He brings expertise in the areas of microfluidics, microfabrication, and experimental fluid mechanics to Kytopen.

Ann is a General Partner at The Engine. She serves as a Board Member for Kytopen, Biobot Analytics, Cellino, Lucy Therapeutics, Quaise, Syzygy, and Vaxess Technologies. Ann was most recently at Sanofi where she held senior roles in business development and strategic venture investment. Prior to Sanofi, she was at Flagship Pioneering. Ann started her career in R&D at 3M Company, working across fields of materials, biology and engineering. Ann holds an MBA from Harvard and a PhD in Chemical Engineering from MIT. She served on the Board of Women in the Enterprise of Science and Technology and is on the Life Science Council of Springboard Enterprises.

Adam Wieschhaus is a Director at Northpond Ventures on the firm’s life science R&D solutions, molecular diagnostics, and environmental sciences teams. Adam is a Board Director at Encodia, Inflammatix, Isolere Bio, IsoPlexis (NASDAQ: ISO), Kytopen, Ori Biotech, Slingshot Biosciences, SpeeDx, Torus Biosystems, Ultivue, and Vestaron.  Adam has experience in business and science as he holds a Ph.D. from the University of Illinois College of Medicine, a B.S. in biochemistry and molecular biology from University of Georgia, and is a CFA charterholder.